Company intelligence / Profile preview

Synerk Pharmaceutical Technology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Synerk Pharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative RNA interference (RNAi) therapeutics. Based in Suzhou, China, the company utilizes its proprietary GalNAc-siRNA conjugation technology to create long-acting treatments for prevalent chronic conditions, particularly in the metabolic and cardiovascular spaces. Its lead candidate, SNK01, is a PCSK9-targeting siRNA for hyperlipidemia, while SNK11 targets angiotensinogen for the treatment of hypertension. Synerk is also actively researching extra-hepatic delivery systems to expand the reach of its RNAi platform beyond liver-related diseases.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Synerk Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synerk Pharmaceutical Technology.

Explore the full profile